These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 15951326)

  • 1. Tramadol disposition in the very young: an attempt to assess in vivo cytochrome P-450 2D6 activity.
    Allegaert K; Anderson BJ; Verbesselt R; Debeer A; de Hoon J; Devlieger H; Van Den Anker JN; Tibboel D
    Br J Anaesth; 2005 Aug; 95(2):231-9. PubMed ID: 15951326
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Covariates of tramadol disposition in the first months of life.
    Allegaert K; van den Anker JN; de Hoon JN; van Schaik RH; Debeer A; Tibboel D; Naulaers G; Anderson BJ
    Br J Anaesth; 2008 Apr; 100(4):525-32. PubMed ID: 18303070
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tramadol and o-desmethyl tramadol clearance maturation and disposition in humans: a pooled pharmacokinetic study.
    Allegaert K; Holford N; Anderson BJ; Holford S; Stuber F; Rochette A; Trocóniz IF; Beier H; de Hoon JN; Pedersen RS; Stamer U
    Clin Pharmacokinet; 2015 Feb; 54(2):167-78. PubMed ID: 25258277
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Postmenstrual age and CYP2D6 polymorphisms determine tramadol o-demethylation in critically ill neonates and infants.
    Allegaert K; van Schaik RH; Vermeersch S; Verbesselt R; Cossey V; Vanhole C; van Fessem M; de Hoon J; van den Anker JN
    Pediatr Res; 2008 Jun; 63(6):674-9. PubMed ID: 18317231
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effects of tramadol on static and dynamic pupillometry in healthy subjects--the relationship between pharmacodynamics, pharmacokinetics and CYP2D6 metaboliser status.
    Fliegert F; Kurth B; Göhler K
    Eur J Clin Pharmacol; 2005 Jun; 61(4):257-66. PubMed ID: 15906019
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of CYP2D6-mediated tramadol O-demethylation in methadone but not buprenorphine maintenance patients.
    Coller JK; Michalakas JR; James HM; Farquharson AL; Colvill J; White JM; Somogyi AA
    Br J Clin Pharmacol; 2012 Nov; 74(5):835-41. PubMed ID: 22369095
    [TBL] [Abstract][Full Text] [Related]  

  • 7. O-demethylation of tramadol in the first months of life.
    Allegaert K; Van den Anker JN; Verbesselt R; de Hoon J; Vanhole C; Tibboel D; Devlieger H
    Eur J Clin Pharmacol; 2005 Dec; 61(11):837-42. PubMed ID: 16283273
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Population pharmacokinetic analysis of tramadol and
    Lee J; Yoo HD; Bae JW; Lee S; Shin KH
    Drug Des Devel Ther; 2019; 13():1751-1761. PubMed ID: 31213765
    [No Abstract]   [Full Text] [Related]  

  • 9. Impact of fraction unbound, CYP3A, and CYP2D6 in vivo activities, and other potential covariates to the clearance of tramadol enantiomers in patients with neuropathic pain.
    de Moraes NV; Lauretti GR; Coelho EB; Godoy AL; Neves DV; Lanchote VL
    Fundam Clin Pharmacol; 2016 Apr; 30(2):153-61. PubMed ID: 26947771
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of the cytochrome P450 2D6*10 genotype on the pharmacokinetics of tramadol in post-operative patients.
    Xu J; Zhang XC; Lv XQ; Xu YY; Wang GX; Jiang B; Cai L; Cai XJ
    Pharmazie; 2014 Feb; 69(2):138-41. PubMed ID: 24640604
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enantioselective pharmacokinetics of tramadol in CYP2D6 extensive and poor metabolizers.
    Pedersen RS; Damkier P; Brøsen K
    Eur J Clin Pharmacol; 2006 Jul; 62(7):513-21. PubMed ID: 16763825
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Physiologically Based Pharmacokinetic Predictions of Tramadol Exposure Throughout Pediatric Life: an Analysis of the Different Clearance Contributors with Emphasis on CYP2D6 Maturation.
    T'jollyn H; Snoeys J; Vermeulen A; Michelet R; Cuyckens F; Mannens G; Van Peer A; Annaert P; Allegaert K; Van Bocxlaer J; Boussery K
    AAPS J; 2015 Nov; 17(6):1376-87. PubMed ID: 26209290
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Population pharmacokinetics of the two enantiomers of tramadol and O-demethyl tramadol after surgery in children.
    Bressolle F; Rochette A; Khier S; Dadure C; Ouaki J; Capdevila X
    Br J Anaesth; 2009 Mar; 102(3):390-9. PubMed ID: 19189983
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of terbinafine and itraconazole on the pharmacokinetics of orally administered tramadol.
    Saarikoski T; Saari TI; Hagelberg NM; Backman JT; Neuvonen PJ; Scheinin M; Olkkola KT; Laine K
    Eur J Clin Pharmacol; 2015 Mar; 71(3):321-7. PubMed ID: 25560051
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of CYP2D6 genetic polymorphism on tramadol pharmacokinetics and pharmacodynamics.
    Gan SH; Ismail R; Wan Adnan WA; Zulmi W
    Mol Diagn Ther; 2007; 11(3):171-81. PubMed ID: 17570739
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pediatric intravenous paracetamol (propacetamol) pharmacokinetics: a population analysis.
    Anderson BJ; Pons G; Autret-Leca E; Allegaert K; Boccard E
    Paediatr Anaesth; 2005 Apr; 15(4):282-92. PubMed ID: 15787918
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of the Ecstasy influence on tramadol and its main metabolite plasma concentration in rats.
    Jamali B; Sheikholeslami B; Hosseinzadeh Ardakani Y; Lavasani H; Rouini MR
    Drug Metab Pers Ther; 2017 Sep; 32(3):137-145. PubMed ID: 28917081
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PBPK and its Virtual Populations: the Impact of Physiology on Pediatric Pharmacokinetic Predictions of Tramadol.
    T'jollyn H; Vermeulen A; Van Bocxlaer J
    AAPS J; 2018 Nov; 21(1):8. PubMed ID: 30498862
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relationship of CYP2D6 genetic polymorphisms and the pharmacokinetics of tramadol in Chinese volunteers.
    Li Q; Wang R; Guo Y; Wen S; Xu L; Wang S
    J Clin Pharm Ther; 2010 Apr; 35(2):239-47. PubMed ID: 20456744
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics of tramadol enantiomers and their respective phase I metabolites in relation to CYP2D6 phenotype.
    García-Quetglas E; Azanza JR; Sádaba B; Muñoz MJ; Gil I; Campanero MA
    Pharmacol Res; 2007 Feb; 55(2):122-30. PubMed ID: 17175164
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.